Immunome, Inc. (IMNM) Tops Q1 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Immunome Reports First Quarter 2025 Financial Results and Provides Business Update
May 12, 2025 4:05 PM EDTBOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended March 31, 2025 and provided a business update.
Immunome continued to build momentum in the first quarter of 2025, said Clay B. Siegall, Ph.D., President and Chief Executive Officer. We... More
